Ceritinib in Combination With Stereotactic Ablative Radiation Metastatic Lung Adenocarcinoma
Status:
Active, not recruiting
Trial end date:
2022-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to see if Ceritinib can target ALK in non-small cell lung cancer
and slow down cancer growth and prevent it from spreading.